Practice Guidelines

CDC Updates Guidelines for Influenza Vaccination for 2010–2011 Season

Am Fam Physician. 2010 Oct 1;82(7):838-844.

Guideline source: Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices

Literature search described? No

Evidence rating system used? No

Published source: MMWR Recommendations and Reports, August 6, 2010, and Morbidity and Mortality Weekly Report, August 13, 2010

Available at: http://cdc.gov/mmwr/preview/mmwrhtml/rr5908a1.htm?s_cid=rr5908a1_w and http://cdc.gov/mmwr/preview/mmwrhtml/mm5931a4.htm

Influenza caused by the 2009 pandemic influenza A (H1N1) virus is expected to continue over the fall and winter of 2010–2011. However, whether the pandemic virus will replace or cocirculate with seasonal H1N1 and H3N2 is not yet known.

Rates of seasonal influenza infection are typically highest among children, and rates of serious illness and death are highest among persons 65 years and older, children younger than two years, and persons with medical conditions that put them at increased risk of complications from influenza. However, last season the risk of complications among adults 19 to 64 years of age who had pandemic H1N1 infection was greater than typically occurs for seasonal influenza.

The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has released updated recommendations on influenza control for the 2010–2011 season. The primary changes to this season's guidelines include the following:

  • Vaccination is recommended for all persons six months and older. Previously, routine vaccination had not been recommended for healthy nonpregnant adults 18 to 49 years of age who were not at risk of occupational exposure to influenza and who were not in close contact with persons at risk of influenza-related complications. However, because a substantial proportion of adults may still be susceptible to infection with 2009 pandemic influenza A (H1N1)-like viruses, the previous recommendation has been expanded to include all adults.

  • As in previous years, all children six months to eight years of age who are receiving seasonal influenza vaccine for the first time should receive two doses. However, this season previously vaccinated children should also receive two doses of vaccine—not one—if last season was the first time they received seasonal influenza vaccine, and if they received only one dose last season (Figure 1). In addition, children six months to eight years of age who did not receive at least one dose of influenza A (H1N1) 2009 monovalent vaccine last season should receive two doses of seasonal influenza vaccine, regardless of their seasonal influenza vaccination history.

  • Age indications have been expanded for two previously approved inactivated vaccines (Table 1). Fluarix is now approved for use in persons three years and older, and Afluria is now approved for use in persons six months and older. However, ACIP recommends that Afluria not be given to children six months to eight years of age. Afluria is antigenically identical to an inactivated influenza vaccine used in Australia in 2010 that was associated with increased frequency of fever and febrile seizures among children in this age group. Afluria can be used if no other age-appropriate vaccine is available for a child five to eight years of age who has a medical condition that increases the risk of influenza complications. However, physicians should discuss the benefits and risks with the parents or caregivers.

  • A new high-dose trivalent inactivated vaccine (Fluzone High-Dose) is available for adults 65 years and older.

  • Seasonal influenza vaccines in 2010–2011 will contain A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens. The influenza A (H1N1) vaccine virus is derived from the 2009 pandemic influenza A (H1N1) virus.

Recommended Influenza Vaccine Doses for Children

Figure 1.

Algorithm for determining the number of vaccine doses recommended for children during the 2010–2011 influenza season.

Adapted from Fiore AE, Uyeki TM, Broder K, et al.; Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):34.

View Large

Recommended Influenza Vaccine Doses for Children


Figure 1.

Algorithm for determining the number of vaccine doses recommended for children during the 2010–2011 influenza season.

Adapted from Fiore AE, Uyeki TM, Broder K, et al.; Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):34.

Recommended Influenza Vaccine Doses for Children


Figure 1.

Algorithm for determining the number of vaccine doses recommended for children during the 2010–2011 influenza season.

Adapted from Fiore AE, Uyeki TM, Broder K, et al.; Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):34.

Table 1.

Vaccines for 2010–2011 Influenza Season

Vaccine type Brand name Manufacturer Dispensing method Mercury content (mcg Hg per 0.5-mL dose) Approved ages Number of doses Route of administration

LAIV*

Flumist

MedImmune

0.2-mL sprayer

0.0

2 to 49 years

1 or 2†

Intranasal

TIV

Afluria

CSL Biotherapies

0.5-mL prefilled syringe

0.0

6 months and older‡

1

Intramuscular§

5.0-mL multidose vial

25.0

TIV

Fluarix

GlaxoSmithKline

0.5-mL prefilled syringe

0.0

3 years and older

1

Intramuscular§

TIV

Flulaval

GlaxoSmithKline

5.0-mL multidose vial

25.0

18 years and older

1

Intramuscular§

TIV

Fluvirin

Novartis Vaccine

0.5-mL prefilled syringe

< 1.0

4 years and older

1 or 2†

Intramuscular§

5.0-mL multidose vial

24.5

TIV

Fluzone

Sanofi Pasteur

0.25-mL prefilled syringe

0.0

6 to 35 months

1 or 2†

Intramuscular§

0.5-mL prefilled syringe

0.0

36 months and older

0.5-mL vial

0.0

36 months and older

5.0-mL multidose vial

25.0

6 months and older

High-dose TIV||

Fluzone High-Dose

Sanofi Pasteur

0.5-mL prefilled syringe

0.0

65 years and older

1

Intramuscular§


LAIV = live attenuated influenza vaccine; TIV = trivalent inactivated vaccine.

*—The recommended dose of LAIV is 0.2 mL divided equally between each nostril. Physicians should consult the medical record of children two to four years of age to identify those with asthma or recurrent wheezing that might indicate asthma. To identify children at greater risk of asthma or wheezing after receiving LAIV, parents or caregivers of children should be asked: “In the past 12 months, have you been told that your child had wheezing or asthma?” Children whose parents or caregivers answer “yes” to this question and children who have asthma or who had a wheezing episode noted in their medical record within the past 12 months should not receive LAIV.

—Children six months to eight years of age who have never received seasonal TIV or who did not receive at least one dose of influenza A (H1N1) 2009 monovalent vaccine should receive two doses, at least four weeks apart. Children who received seasonal influenza vaccine for the first time in the 2009–2010 season but who received only one dose should receive two doses this season, at least four weeks apart.

—Although Afluria is approved for use in children six months and older, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that this vaccine not be given to children six months to eight years of age. Afluria is antigenically identical to an inactivated influenza vaccine used in Australia in 2010 that was associated with increased frequency of fever and febrile seizures among children in this age group. If no other age-appropriate vaccine is available for a child five to eight years of age who has a medical condition that increases the risk of influenza complications, Afluria can be used. However, physicians should discuss the benefits and risks with the parents or caregivers.

§—The deltoid muscle is the recommended vaccination site in adults and older children; the anterolateral aspect of the thigh is the recommended site in infants and young children.

||—A 0.5-mL dose of high-dose TIV contains 60 mcg each of A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens.

Adapted from Fiore AE, Uyeki TM, Broder K, et al.; Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):17, with additional information from Centers for Disease Control and Prevention. Update: recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010–11. MMWR Morb Mortal Wkly Rep. 2010;59(31):989–992.

Table 1.   Vaccines for 2010–2011 Influenza Season

View Table

Table 1.

Vaccines for 2010–2011 Influenza Season

Vaccine type Brand name Manufacturer Dispensing method Mercury content (mcg Hg per 0.5-mL dose) Approved ages Number of doses Route of administration

LAIV*

Flumist

MedImmune

0.2-mL sprayer

0.0

2 to 49 years

1 or 2†

Intranasal

TIV

Afluria

CSL Biotherapies

0.5-mL prefilled syringe

0.0

6 months and older‡

1

Intramuscular§

5.0-mL multidose vial

25.0

TIV

Fluarix

GlaxoSmithKline

0.5-mL prefilled syringe

0.0

3 years and older

1

Intramuscular§

TIV

Flulaval

GlaxoSmithKline

5.0-mL multidose vial

25.0

18 years and older

1

Intramuscular§

TIV

Fluvirin

Novartis Vaccine

0.5-mL prefilled syringe

< 1.0

4 years and older

1 or 2†

Intramuscular§

5.0-mL multidose vial

24.5

TIV

Fluzone

Sanofi Pasteur

0.25-mL prefilled syringe

0.0

6 to 35 months

1 or 2†

Intramuscular§

0.5-mL prefilled syringe

0.0

36 months and older

0.5-mL vial

0.0

36 months and older

5.0-mL multidose vial

25.0

6 months and older

High-dose TIV||

Fluzone High-Dose

Sanofi Pasteur

0.5-mL prefilled syringe

0.0

65 years and older

1

Intramuscular§


LAIV = live attenuated influenza vaccine; TIV = trivalent inactivated vaccine.

*—The recommended dose of LAIV is 0.2 mL divided equally between each nostril. Physicians should consult the medical record of children two to four years of age to identify those with asthma or recurrent wheezing that might indicate asthma. To identify children at greater risk of asthma or wheezing after receiving LAIV, parents or caregivers of children should be asked: “In the past 12 months, have you been told that your child had wheezing or asthma?” Children whose parents or caregivers answer “yes” to this question and children who have asthma or who had a wheezing episode noted in their medical record within the past 12 months should not receive LAIV.

—Children six months to eight years of age who have never received seasonal TIV or who did not receive at least one dose of influenza A (H1N1) 2009 monovalent vaccine should receive two doses, at least four weeks apart. Children who received seasonal influenza vaccine for the first time in the 2009–2010 season but who received only one dose should receive two doses this season, at least four weeks apart.

—Although Afluria is approved for use in children six months and older, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that this vaccine not be given to children six months to eight years of age. Afluria is antigenically identical to an inactivated influenza vaccine used in Australia in 2010 that was associated with increased frequency of fever and febrile seizures among children in this age group. If no other age-appropriate vaccine is available for a child five to eight years of age who has a medical condition that increases the risk of influenza complications, Afluria can be used. However, physicians should discuss the benefits and risks with the parents or caregivers.

§—The deltoid muscle is the recommended vaccination site in adults and older children; the anterolateral aspect of the thigh is the recommended site in infants and young children.

||—A 0.5-mL dose of high-dose TIV contains 60 mcg each of A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens.

Adapted from Fiore AE, Uyeki TM, Broder K, et al.; Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):17, with additional information from Centers for Disease Control and Prevention. Update: recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010–11. MMWR Morb Mortal Wkly Rep. 2010;59(31):989–992.

Healthy nonpregnant persons two to 49 years of age can choose to receive inactivated vaccine or live attenuated vaccine (Table 2). Adults older than 65 years can be given standard-dose or high-dose inactivated vaccine. Trivalent inactivated vaccine is licensed for use in persons with high-risk conditions (Table 2). Live attenuated vaccine is licensed for use only in persons two to 49 years of age. The safety of live attenuated vaccine has not been established in persons with underlying medical conditions that confer a higher risk of influenza complications.

Table 2.

Comparison of Influenza Vaccines

Factor LAIV TIV

Route of administration

Intranasal

Intramuscular

Type of vaccine

Live virus

Inactivated virus

Virus strains included

A/California/7/2009 (H1N1)

A/California/7/2009 (H1N1)

A/Perth/16/2009 (H3N2)

A/Perth/16/2009 (H3N2)

B/Brisbane/60/2008

B/Brisbane/60/2008

Frequency of virus strain updates

Annually

Annually

Frequency of administration

Annually*

Annually*

Approved ages

2 to 49 years†

6 months and older‡

Interval between doses in children 6 months to 8 years of age who are receiving vaccine for first time

At least 4 weeks

At least 4 weeks

Can be given to persons with medical risk factors for influenza-related complications†

No

Yes

Can be given to children with asthma or to children 2 to 4 years of age with a history of wheezing in the past year§

No

Yes

Can be given to family members or close contacts of immunosuppressed persons not requiring a protected environment

Yes

Yes

Can be given to family members or close contacts of immunosuppressed persons requiring a protected environment

No

Yes

Can be given to family members or close contacts of persons at higher risk but not severely immunosuppressed (e.g., pregnant women)

Yes

Yes

Can be given simultaneously with other vaccines

Yes||

Yes¶

Can be given within 4 weeks of a live vaccine

Prudent to space at least 4 weeks apart

Yes

Can be given within 4 weeks of an inactivated vaccine

Yes

Yes


LAIV = live attenuated influenza vaccine; TIV = trivalent inactivated vaccine.

*—Children six months to eight years of age who have never received seasonal TIV or who did not receive at least one dose of influenza A (H1N1) 2009 monovalent vaccine should receive two doses, at least four weeks apart. Children who received seasonal influenza vaccine for the first time in the 2009–2010 season but who received only one dose should receive two doses this season, at least four weeks apart.

—Persons at higher risk for influenza-related complications should not receive LAIV. Such persons include those who have chronic pulmonary disease (including asthma), cardiovascular disease (except hypertension), metabolic disorders (including diabetes mellitus), or renal, hepatic, neurologic, or hematologic disorders; those who are immunosuppressed (including immunosuppression caused by medications or human immunodeficiency virus infection); those who are or will be pregnant during the influenza season; those six months to 18 years of age who are on long-term aspirin therapy and may be at risk of Reye syndrome; and residents of nursing homes and other long-term care facilities.

—Approved ages vary by formulation; see Table 1.

§—Physicians should consult the medical record of children two to four years of age to identify those with asthma or recurrent wheezing that might indicate asthma. To identify children at greater risk of asthma or wheezing after receiving LAIV, parents or caregivers of children should be asked: “In the past 12 months, have you been told that your child had wheezing or asthma?” Children whose parents or caregivers answer “yes” to this question and children who have asthma or who had a wheezing episode noted in their medical record within the past 12 months should not receive LAIV.

||—Coadministration of LAIV has been systematically evaluated only among children 12 to 15 months of age who also received measles, mumps, and rubella vaccine or varicella vaccine.

—Coadministration of TIV has been systematically evaluated only among adults who also received pneumococcal polysaccharide or zoster vaccine.

Adapted from Fiore AE, Uyeki TM, Broder K, et al.; Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):11.

Table 2.   Comparison of Influenza Vaccines

View Table

Table 2.

Comparison of Influenza Vaccines

Factor LAIV TIV

Route of administration

Intranasal

Intramuscular

Type of vaccine

Live virus

Inactivated virus

Virus strains included

A/California/7/2009 (H1N1)

A/California/7/2009 (H1N1)

A/Perth/16/2009 (H3N2)

A/Perth/16/2009 (H3N2)

B/Brisbane/60/2008

B/Brisbane/60/2008

Frequency of virus strain updates

Annually

Annually

Frequency of administration

Annually*

Annually*

Approved ages

2 to 49 years†

6 months and older‡

Interval between doses in children 6 months to 8 years of age who are receiving vaccine for first time

At least 4 weeks

At least 4 weeks

Can be given to persons with medical risk factors for influenza-related complications†

No

Yes

Can be given to children with asthma or to children 2 to 4 years of age with a history of wheezing in the past year§

No

Yes

Can be given to family members or close contacts of immunosuppressed persons not requiring a protected environment

Yes

Yes

Can be given to family members or close contacts of immunosuppressed persons requiring a protected environment

No

Yes

Can be given to family members or close contacts of persons at higher risk but not severely immunosuppressed (e.g., pregnant women)

Yes

Yes

Can be given simultaneously with other vaccines

Yes||

Yes¶

Can be given within 4 weeks of a live vaccine

Prudent to space at least 4 weeks apart

Yes

Can be given within 4 weeks of an inactivated vaccine

Yes

Yes


LAIV = live attenuated influenza vaccine; TIV = trivalent inactivated vaccine.

*—Children six months to eight years of age who have never received seasonal TIV or who did not receive at least one dose of influenza A (H1N1) 2009 monovalent vaccine should receive two doses, at least four weeks apart. Children who received seasonal influenza vaccine for the first time in the 2009–2010 season but who received only one dose should receive two doses this season, at least four weeks apart.

—Persons at higher risk for influenza-related complications should not receive LAIV. Such persons include those who have chronic pulmonary disease (including asthma), cardiovascular disease (except hypertension), metabolic disorders (including diabetes mellitus), or renal, hepatic, neurologic, or hematologic disorders; those who are immunosuppressed (including immunosuppression caused by medications or human immunodeficiency virus infection); those who are or will be pregnant during the influenza season; those six months to 18 years of age who are on long-term aspirin therapy and may be at risk of Reye syndrome; and residents of nursing homes and other long-term care facilities.

—Approved ages vary by formulation; see Table 1.

§—Physicians should consult the medical record of children two to four years of age to identify those with asthma or recurrent wheezing that might indicate asthma. To identify children at greater risk of asthma or wheezing after receiving LAIV, parents or caregivers of children should be asked: “In the past 12 months, have you been told that your child had wheezing or asthma?” Children whose parents or caregivers answer “yes” to this question and children who have asthma or who had a wheezing episode noted in their medical record within the past 12 months should not receive LAIV.

||—Coadministration of LAIV has been systematically evaluated only among children 12 to 15 months of age who also received measles, mumps, and rubella vaccine or varicella vaccine.

—Coadministration of TIV has been systematically evaluated only among adults who also received pneumococcal polysaccharide or zoster vaccine.

Adapted from Fiore AE, Uyeki TM, Broder K, et al.; Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):11.

Routine annual vaccination should be emphasized for certain groups at higher risk of influenza or influenza-related complications, including children six months to 18 years of age and adults 50 years and older. These persons, their household and close contacts, and all health care professionals should be a focus of vaccination efforts.

The capacity now exists to produce sufficient influenza vaccine to meet a predicted increase in demand. However, the annual supply and timing of vaccine distribution cannot be guaranteed. If vaccine supply is limited, vaccination efforts should focus on the following groups:

  • Children six months to four years of age

  • Adults 50 years and older

  • Persons who have chronic pulmonary disease (including asthma); cardiovascular disease (except hypertension); or renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)

  • Persons who are immunosuppressed (including immunosuppression caused by medications or by human immunodeficiency virus infection)

  • Pregnant women

  • Children six months to 18 years of age who are on long-term aspirin therapy and who may be at risk for Reye syndrome after influenza virus infection

  • Residents of nursing homes and other long-term care facilities

  • American Indians and Alaska natives

  • Persons who are morbidly obese (body mass index of 40 kg per m2 or greater)

  • Health care professionals

  • Household contacts and caregivers of children younger than five years and adults 50 years or older, with particular emphasis on vaccinating contacts of children younger than six months

  • Household contacts and caregivers of persons with medical conditions that put them at higher risk of severe complications from influenza.

Antiviral Treatment

Antiviral medications with activity against influenza viruses are useful adjuncts in the prevention of influenza, and effective when used early in the course of illness for treatment. Four influenza antiviral agents are licensed in the United States: amantadine, rimantadine (Flumadine), zanamivir (Relenza), and oseltamivir (Tamiflu). Investigational antiviral medications, such as peramivir and intravenous formulations of zanamivir, may be available under investigational new drug protocols.

Approximately 99 percent of seasonal influenza A (H1N1) viruses (i.e., H1N1 viruses not associated with the 2009 pandemic) tested in the United States were resistant to oseltamivir. As of June 2010, most 2009 pandemic influenza A (H1N1) virus strains remained sensitive to oseltamivir, and all were sensitive to zanamivir. ACIP recommendations for antiviral use will be published later this year.

Coverage of guidelines from other organizations does not imply endorsement by AFP or the AAFP.


Copyright © 2010 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article